Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02225665 | Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART | PHASE1 | COMPLETED | 8 | — | — | Aug 1, 2014 | Jun 1, 2018 | Mar 19, 2021 | 5 | United States |
Number of Participants with Treatment related Adverse Events in subjects who received any portion of the SB-728mR-T infusion
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | - |
| Cohort 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SB-728mR-T | GENETIC | -SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells) |
| Cyclophosphamide | DRUG | \- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion |
Inclusion Criteria: * Male or female, 18 years of age or older with documented HIV diagnosis. * Must be willing to comply with study-mandated evaluations; including discontinuation of current antiretroviral therapy during the treatment interruption. * Initiated HAART therapy within (≤) 1 year of HI...